{"id":7614,"date":"2025-06-25T17:54:58","date_gmt":"2025-06-25T14:54:58","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7614"},"modified":"2025-06-25T17:54:58","modified_gmt":"2025-06-25T14:54:58","slug":"scientific-summary-a-new-fda-clearance-for-the-aventus-thrombectomy-system-was-officially-published-on","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/scientific-summary-a-new-fda-clearance-for-the-aventus-thrombectomy-system-was-officially-published-on\/","title":{"rendered":"Scientific Summary   A new FDA clearance for the Aventus Thrombectomy System was officially published on\u00a0"},"content":{"rendered":"<div>Scientific Summary<\/div>\n<div><\/div>\n<div>A new FDA clearance for the Aventus Thrombectomy System was officially published on<\/div>\n<div>June 16, 2025, marking a key development in PE management.<\/div>\n<div><\/div>\n<div><span> 1. Device Overview:<\/span><\/div>\n<div><span> \u2022 The Aventus Thrombectomy System, developed by Inquis Medical (California), has received FDA clearance for use in treating pulmonary embolism (PE).<\/span><\/div>\n<div><span> \u2022 It is a next-generation mechanical thrombectomy system previously approved for removing clots from peripheral arteries.<\/span><\/div>\n<div><span> 2. New Indication:<\/span><\/div>\n<div><span> \u2022 The new FDA clearance expands its indication to include intermediate-risk PE patients, marking a significant development in PE management.<\/span><\/div>\n<div><span> 3. Clinical Evidence:<\/span><\/div>\n<div><span> \u2022 Clearance was based on an IDE clinical study involving 120 patients across 22 U.S. sites.<\/span><\/div>\n<div><span> \u2022 Results showed:<\/span><\/div>\n<div><span> \u2022 No device-related major adverse events<\/span><\/div>\n<div><span> \u2022 Significant improvement in right heart strain, a key marker in PE outcomes.<\/span><\/div>\n<div><span> \u2022 The full results were published in JSCAI.<\/span><\/div>\n<div><span> 4. Key Innovation:<\/span><\/div>\n<div><span> \u2022 Aventus is the only thrombectomy system with integrated tissue-sensing technology, allowing:<\/span><\/div>\n<div><span> \u2022 Accurate clot removal<\/span><\/div>\n<div><span> \u2022 Simultaneous blood return<\/span><\/div>\n<div><span> \u2022 Reduced procedural complexity<\/span><\/div>\n<div><span> \u2022 One-platform operation without requiring multiple tools<\/span><\/div>\n<div><span> 5.\u00a0 Intermediate-risk PE (also known as submassive PE) accounts for an estimated 30\u201350% of all pulmonary embolism cases. These patients are hemodynamically stable but show signs of right heart strain or myocardial injury.<\/span><\/div>\n<div><\/div>\n<div>Note: This information is based on guideline data and clinical registry findings, not part of the original article.<\/div>\n<div><\/div>\n<div>Massive PE accounts for approximately 5\u201310% of cases, whereas the majority of PE patients (~90\u201395%) fall into intermediate- or low-risk categories.<\/div>\n<div><\/div>\n<div>\u200fhttps:\/\/www.jscai.org\/article\/S2772-9303(25)01103-2\/fulltext<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Scientific Summary A new FDA clearance for the Aventus Thrombectomy System was officially published on June 16, 2025, marking a key development in PE management. 1. Device Overview: \u2022 The Aventus Thrombectomy System, developed by Inquis Medical (California), has received FDA clearance for use in treating pulmonary embolism (PE). \u2022 It is a next-generation mechanical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7614","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7614"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7614\/revisions"}],"predecessor-version":[{"id":7618,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7614\/revisions\/7618"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}